Market Analysis and Insights:
Due to the COVID-19 pandemic, the global CAR T-Cell Therapy market size is estimated to be worth US$ 2805.83 million in 2022 and is forecast to a readjusted size of US$ 13503.04 million by 2028 with a CAGR of 29.94% during the forecast period 2022-2028.
The global major manufacturers of CAR T-Cell Therapy include Novartis, Gilead Sciences, Bristol-Myers Squibb, J & J, JW Therapeutics, FOSUNKite, etc. In terms of revenue, the global three largest players hold a 99.32% market share of CAR T-Cell Therapy in 2021.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global CAR T-Cell Therapy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global CAR T-Cell Therapy market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global CAR T-Cell Therapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global CAR T-Cell Therapy market.
Scope and Market Size:
CAR T-Cell Therapy market is segmented by players, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global CAR T-Cell Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2017-2028.
By Company
- Novartis
- Gilead Sciences
- Bristol-Myers Squibb
- J & J
- JW Therapeutics
- FOSUNKite
- CARsgen Therapeutics (Pipeline)
- Autolus Therapeutics(Pipeline)
- Sorrento Therapeutics(Pipeline)
- Mustang Bio(Pipeline)
- Bluebird Bio(Pipeline)
- Cellectis(Pipeline)
- Allogene Therapeutics(Pipeline)
- Celyad(Pipeline)
Segment by Type
- CD19-targeted
- BCMA-targeted
Segment by Application
- Lymphoma
- Multiple Myeloma
By Region
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Rest of Asia
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Rest of Europe
- South America
- Brazil
- Rest of South America
TABLE OF CONTENTS
1 REPORT OVERVIEW
- 1.1 Study Scope
- 1.2 Market Analysis by Type
- 1.2.1 Global CAR T-Cell Therapy Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
- 1.2.2 CD19-targeted
- 1.2.3 BCMA-targeted
- 1.3 Market by Application
- 1.3.1 Global CAR T-Cell Therapy Market Share by Application: 2017 VS 2021 VS 2028
- 1.3.2 Lymphoma
- 1.3.3 Multiple Myeloma
- 1.4 Study Objectives
- 1.5 Years Considered
2 GLOBAL GROWTH TRENDS
- 2.1 Global CAR T-Cell Therapy Market Perspective (2017-2028)
- 2.2 CAR T-Cell Therapy Growth Trends by Region
- 2.2.1 CAR T-Cell Therapy Market Size by Region: 2017 VS 2021 VS 2028
- 2.2.2 CAR T-Cell Therapy Historic Market Size by Region (2017-2022)
- 2.2.3 CAR T-Cell Therapy Forecasted Market Size by Region (2023-2028)
- 2.3 CAR T-Cell Therapy Market Dynamics
- 2.3.1 CAR T-Cell Therapy Industry Trends
- 2.3.2 CAR T-Cell Therapy Market Drivers
- 2.3.3 CAR T-Cell Therapy Market Challenges
- 2.3.4 CAR T-Cell Therapy Market Restraints
- 2.3.5 Analysis of Entry Barrier CAR T-Cell Therapy on Global Market and China Market
- 2.4 Market Ecosystem and Value Chain Analysis
3 COMPETITION LANDSCAPE BY KEY PLAYERS
- 3.1 Global Top CAR T-Cell Therapy Players by Revenue
- 3.1.1 Global Top CAR T-Cell Therapy Players by Revenue (2017-2022)
- 3.1.2 Global CAR T-Cell Therapy Revenue Market Share by Players (2017-2022)
- 3.2 Global CAR T-Cell Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.3 Players Covered: Ranking by CAR T-Cell Therapy Revenue
- 3.4 Global CAR T-Cell Therapy Market Concentration Ratio
- 3.4.1 Global CAR T-Cell Therapy Market Concentration Ratio (CR5 and HHI)
- 3.4.2 Global Top 5 Companies by CAR T-Cell Therapy Revenue in 2021
- 3.5 CAR T-Cell Therapy Key Players Head office and Area Served
- 3.6 Key Players CAR T-Cell Therapy Product Solution and Service
- 3.7 Date of Enter into CAR T-Cell Therapy Market
- 3.8 Mergers & Acquisitions, Expansion Plans
4 CAR T-CELL THERAPY BREAKDOWN DATA BY TYPE
- 4.1 Global CAR T-Cell Therapy Historic Market Size by Type (2017-2022)
- 4.2 Global CAR T-Cell Therapy Forecasted Market Size by Type (2023-2028)
5 CAR T-CELL THERAPY BREAKDOWN DATA BY APPLICATION
- 5.1 Global CAR T-Cell Therapy Historic Market Size by Application (2017-2022)
- 5.2 Global CAR T-Cell Therapy Forecasted Market Size by Application (2023-2028)
6 NORTH AMERICA
- 6.1 North America CAR T-Cell Therapy Market Size (2017-2028)
- 6.2 North America CAR T-Cell Therapy Market Size by Type
- 6.2.1 North America CAR T-Cell Therapy Market Size by Type (2017-2022)
- 6.2.2 North America CAR T-Cell Therapy Market Size by Type (2023-2028)
- 6.2.3 North America CAR T-Cell Therapy Market Share by Type (2017-2028)
- 6.3 North America CAR T-Cell Therapy Market Size by Application
- 6.3.1 North America CAR T-Cell Therapy Market Size by Application (2017-2022)
- 6.3.2 North America CAR T-Cell Therapy Market Size by Application (2023-2028)
- 6.3.3 North America CAR T-Cell Therapy Market Share by Application (2017-2028)
- 6.4 North America CAR T-Cell Therapy Market Size by Country
- 6.4.1 North America CAR T-Cell Therapy Market Size by Country (2017-2022)
- 6.4.2 North America CAR T-Cell Therapy Market Share by Country (2023-2028)
- 6.4.3 United States
- 6.4.4 Canada
- 6.4.5 Mexico
7 EUROPE
- 7.1 Europe CAR T-Cell Therapy Market Size (2017-2028)
- 7.2 Europe CAR T-Cell Therapy Market Size by Type
- 7.2.1 Europe CAR T-Cell Therapy Market Size by Type (2017-2022)
- 7.2.2 Europe CAR T-Cell Therapy Market Size by Type (2023-2028)
- 7.2.3 Europe CAR T-Cell Therapy Market Share by Type (2017-2028)
- 7.3 Europe CAR T-Cell Therapy Market Size by Application
- 7.3.1 Europe CAR T-Cell Therapy Market Size by Application (2017-2022)
- 7.3.2 Europe CAR T-Cell Therapy Market Size by Application (2023-2028)
- 7.3.3 Europe CAR T-Cell Therapy Market Share by Application (2017-2028)
- 7.4 Europe CAR T-Cell Therapy Market Size by Country
- 7.4.1 Europe CAR T-Cell Therapy Market Size by Country (2017-2022)
- 7.4.2 Europe CAR T-Cell Therapy Market Size by Country (2023-2028)
- 7.4.3 Germany
- 7.4.4 France
- 7.4.5 U.K.
- 7.4.6 Italy
8 ASIA-PACIFIC
- 8.1 Asia-Pacific CAR T-Cell Therapy Market Size (2017-2028)
- 8.2 Asia-Pacific CAR T-Cell Therapy Market Size by Type
- 8.2.1 Asia-Pacific CAR T-Cell Therapy Market Size by Type (2017-2022)
- 8.2.2 Asia-Pacific CAR T-Cell Therapy Market Size by Type (2023-2028)
- 8.2.3 Asia-Pacific CAR T-Cell Therapy Market Share by Type (2019-2028)
- 8.3 Asia-Pacific CAR T-Cell Therapy Market Size by Application
- 8.3.1 Asia-Pacific CAR T-Cell Therapy Market Size by Application (2017-2022)
- 8.3.2 Asia-Pacific CAR T-Cell Therapy Market Size by Application (2023-2028)
- 8.3.3 Asia-Pacific CAR T-Cell Therapy Market Share by Application (2019-2028)
- 8.4 Asia-Pacific CAR T-Cell Therapy Market Size by Region
- 8.4.1 Asia-Pacific CAR T-Cell Therapy Market Size by Region (2017-2022)
- 8.4.2 Asia-Pacific CAR T-Cell Therapy Market Size by Region (2023-2028)
- 8.4.3 China
- 8.4.4 Japan
- 8.4.5 South Korea
- 8.4.6 India
9 SOUTH AMERICA
- 9.1 South America CAR T-Cell Therapy Market Size (2017-2028)
- 9.2 South America CAR T-Cell Therapy Market Size by Type
- 9.2.1 South America CAR T-Cell Therapy Market Size by Type (2017-2022)
- 9.2.2 South America CAR T-Cell Therapy Market Size by Type (2023-2028)
- 9.2.3 South America CAR T-Cell Therapy Market Share by Type (2022-2028)
- 9.3 South America CAR T-Cell Therapy Market Size by Application
- 9.3.1 South America CAR T-Cell Therapy Market Size by Application (2017-2022)
- 9.3.2 South America CAR T-Cell Therapy Market Size by Application (2023-2028)
- 9.3.3 South America CAR T-Cell Therapy Market Share by Application (2022-2028)
- 9.4 South America CAR T-Cell Therapy Market Size by Country
- 9.4.1 South America CAR T-Cell Therapy Market Size by Country (2017-2022)
- 9.4.2 South America CAR T-Cell Therapy Market Size by Country (2023-2028)
- 9.4.3 Brazil
10 MIDDLE EAST & AFRICA
- 10.1 Middle East & Africa CAR T-Cell Therapy Market Size (2017-2028)
- 10.2 Middle East & Africa CAR T-Cell Therapy Market Size by Type
- 10.2.1 Middle East & Africa CAR T-Cell Therapy Market Size by Type (2017-2022)
- 10.2.2 Middle East & Africa CAR T-Cell Therapy Market Size by Type (2023-2028)
- 10.2.3 Middle East & Africa CAR T-Cell Therapy Market Share by Type (2025-2028)
- 10.3 Middle East & Africa CAR T-Cell Therapy Market Size by Application
- 10.3.1 Middle East & Africa CAR T-Cell Therapy Market Size by Application (2017-2022)
- 10.3.2 Middle East & Africa CAR T-Cell Therapy Market Size by Application (2023-2028)
- 10.3.3 Middle East & Africa CAR T-Cell Therapy Market Share by Application (2025-2028)
- 10.4 Middle East & Africa CAR T-Cell Therapy Market Size by Country
- 10.4.1 Middle East & Africa CAR T-Cell Therapy Market Size by Country (2017-2022)
- 10.4.2 Middle East & Africa CAR T-Cell Therapy Market Size by Country (2023-2028)
- 10.4.3 Middle East
- 10.4.4 Africa
11 KEY PLAYERS PROFILES
- 11.1 Novartis
- 11.1.1 Novartis Company Details
- 11.1.2 Novartis Business Overview
- 11.1.3 Novartis CAR T-Cell Therapy Introduction
- 11.1.4 Novartis Revenue in CAR T-Cell Therapy Business (2017-2022)
- 11.1.5 Novartis Recent Development
- 11.2 Gilead Sciences
- 11.2.1 Gilead Sciences Company Details
- 11.2.2 Gilead Sciences Business Overview
- 11.2.3 Gilead Sciences CAR T-Cell Therapy Introduction
- 11.2.4 Gilead Sciences Revenue in CAR T-Cell Therapy Business (2017-2022)
- 11.2.5 Gilead Sciences Recent Development
- 11.3 Bristol-Myers Squibb
- 11.3.1 Bristol-Myers Squibb Company Details
- 11.3.2 Bristol-Myers Squibb Business Overview
- 11.3.3 Bristol-Myers Squibb CAR T-Cell Therapy Introduction
- 11.3.4 Bristol-Myers Squibb Revenue in CAR T-Cell Therapy Business (2017-2022)
- 11.3.5 Bristol-Myers Squibb Recent Development
- 11.4 J & J
- 11.4.1 J & J Company Details
- 11.4.2 J & J Business Overview
- 11.4.3 J & J CAR T-Cell Therapy Introduction
- 11.4.4 J & J Revenue in CAR T-Cell Therapy Business (2017-2022)
- 11.4.5 J & J Recent Development
- 11.5 JW Therapeutics
- 11.5.1 JW Therapeutics Company Details
- 11.5.2 JW Therapeutics Business Overview
- 11.5.3 JW Therapeutics CAR T-Cell Therapy Introduction
- 11.5.4 JW Therapeutics Revenue in CAR T-Cell Therapy Business (2017-2022)
- 11.5.5 JW Therapeutics Recent Development
- 11.6 FOSUNKite
- 11.6.1 FOSUNKite Company Details
- 11.6.2 FOSUNKite Business Overview
- 11.6.3 FOSUNKite CAR T-Cell Therapy Introduction
- 11.6.4 FOSUNKite Revenue in CAR T-Cell Therapy Business (2017-2022)
- 11.6.5 FOSUNKite Recent Development
- 11.7 CARsgen Therapeutics (Pipeline)
- 11.7.1 CARsgen Therapeutics Company Details
- 11.7.2 CARsgen Therapeutics Business Overview
- 11.7.3 CARsgen Therapeutics CAR T-Cell Therapy Introduction
- 11.8 Autolus Therapeutics (Pipeline)
- 11.8.1 Autolus Therapeutics Company Details
- 11.8.2 Autolus Therapeutics Business Overview
- 11.8.3 Autolus Therapeutics CAR T-Cell Therapy Introduction
- 11.9 Sorrento Therapeutics (Pipeline)
- 11.9.1 Sorrento Therapeutics Company Details
- 11.9.2 Sorrento Therapeutics Business Overview
- 11.9.3 Sorrento Therapeutics CAR T-Cell Therapy Introduction
- 11.10 Mustang Bio (Pipeline)
- 11.10.1 Mustang Bio Company Details
- 11.10.2 Mustang Bio Business Overview
- 11.10.3 Mustang Bio CAR T-Cell Therapy Introduction
- 11.11 Bluebird Bio (Pipeline)
- 11.11.1 Bluebird Bio Company Details
- 11.11.2 Bluebird Bio Business Overview
- 11.11.3 Bluebird Bio CAR T-Cell Therapy Introduction
- 11.11.4 Bluebird Bio Recent Development
- 11.12 Cellectis (Pipeline)
- 11.12.1 Cellectis Company Details
- 11.12.2 Cellectis Business Overview
- 11.12.3 Cellectis CAR T-Cell Therapy Introduction
- 11.13 Allogene Therapeutics (Pipeline)
- 11.13.1 Allogene Therapeutics Company Details
- 11.13.2 Allogene Therapeutics Business Overview
- 11.13.3 Allogene Therapeutics CAR T-Cell Therapy Introduction
- 11.14 Celyad (Pipeline)
- 11.14.1 Celyad Company Details
- 11.14.2 Celyad Business Overview
- 11.14.3 Celyad CAR T-Cell Therapy Introduction
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
- 13.1 Methodology/Research Approach
- 13.1.1 Research Programs/Design
- 13.1.2 Market Size Estimation
- 13.1.3 Market Breakdown and Data Triangulation
- 13.2 Data Source
- 13.2.1 Secondary Sources
- 13.2.2 Primary Sources
- 13.3 Author List
- 13.4 Disclaimer